We are here to assist you.
Health Advisor
+91-8877772277Available 7 days a week
10:00 AM – 6:00 PM to support you with urgent concerns and guide you toward the right care.
Explore the most common types of lung cancer, particularly in smokers, including SCLC and NSCLC. Learn about risk factors, symptoms, diagnosis, treatment, and the vital importance of quitting smoking.

Lung cancer remains a significant health concern globally, and smoking is undeniably the leading cause. While anyone can develop lung cancer, individuals who smoke are at a substantially higher risk. This article delves into the most common types of lung cancer found in smokers, their characteristics, and the importance of quitting.
Lung cancer is broadly classified into two main types based on how the cells look under a microscope: Small Cell Lung Cancer (SCLC) and Non-Small Cell Lung Cancer (NSCLC). This distinction is crucial because the types behave differently and are treated differently.
SCLC, also known as oat cell cancer, accounts for about 15% to 20% of all lung cancer cases. The defining characteristic of SCLC is that it occurs almost exclusively in people who smoke. It is very rare in individuals who have never smoked. SCLC is known for its rapid growth and its tendency to spread quickly to other parts of the body (metastasize). Due to its aggressive nature, SCLC often requires prompt and intensive treatment, typically involving chemotherapy and radiation therapy, often used in combination.
NSCLC is the more common type of lung cancer, making up about 80% to 85% of all lung cancer diagnoses. While SCLC is almost exclusively linked to smoking, NSCLC can occur in both smokers and non-smokers. However, smokers are still at a significantly higher risk of developing NSCLC compared to non-smokers. NSCLC itself is further divided into several subtypes, including:
The connection between smoking and lung cancer is undeniable. Smoking is the leading cause of lung cancer, responsible for an estimated 80% to 90% of all lung cancer deaths. The risk of developing lung cancer increases with the number of cigarettes smoked and the duration of smoking. Men who smoke have a 23 times higher risk of developing lung cancer, while women who smoke have a 13 times higher risk compared to those who have never smoked.
It's important to understand that smoking is linked to all types of lung cancer, but SCLC is almost exclusively found in smokers. Even a small number of cigarettes per day can increase your risk.
The single most effective way to reduce your risk of lung cancer is to quit smoking. The benefits of quitting start almost immediately and continue to grow over time. For every year you remain smoke-free, your risk of lung cancer decreases. Quitting at a younger age, particularly before the age of 40, can dramatically reduce your risk, potentially bringing it close to that of someone who has never smoked.
Even if you have smoked for many years or have already been diagnosed with lung cancer, quitting can still improve your prognosis and increase your chances of survival. It's never too late to quit.
While smoking is the primary risk factor, other factors can also contribute to the development of lung cancer:
Diagnosing lung cancer typically involves a combination of methods:
Treatment for lung cancer depends heavily on the type of cancer (SCLC or NSCLC), its stage, the patient's overall health, and their preferences. Common treatment modalities include:
It is crucial to consult a doctor if you experience any persistent symptoms that could indicate lung cancer, especially if you have a history of smoking. These symptoms may include:
If you are a smoker, regular health check-ups are highly recommended. Discuss your smoking habits and any concerns with your doctor. Early detection significantly improves the chances of successful treatment.
No, not all lung cancer is caused by smoking. While smoking is the leading cause and significantly increases risk, lung cancer can also occur in people who have never smoked due to other risk factors like environmental exposures, air pollution, and genetic predispositions.
The overall 5-year survival rate for lung cancer in India can vary widely depending on the stage at diagnosis and the type of cancer. Generally, lung cancer has a lower survival rate compared to some other cancers, but advancements in treatment and early detection are improving outcomes. For SCLC, the prognosis is often poorer due to its aggressive nature. For NSCLC, survival rates are better, especially when detected early.
Quitting smoking can significantly reduce your risk of developing lung cancer and improve your overall lung health. While some damage may be irreversible, your lungs have a remarkable ability to heal. Quitting allows the cilia (tiny hair-like structures that clear mucus) to start functioning again, reducing the risk of infections and improving breathing over time.
SCLC is challenging to treat due to its aggressive nature and tendency to spread early. While a cure may be difficult to achieve, treatments like chemotherapy and radiation can help control the cancer, alleviate symptoms, and prolong life. Some individuals may achieve remission, where cancer is undetectable, but recurrence is common.
Adenocarcinoma starts in the mucus-producing cells of the lungs and is the most common type in non-smokers and former smokers. Squamous cell carcinoma starts in the flat cells lining the airways and is strongly linked to smoking, often found near the center of the lungs.
Learn about potential side effects of CML treatments like TKIs, interferon, chemotherapy, and stem cell transplants. Understand what to expect and how to communicate with your doctor for effective management.
April 1, 2026

Discover essential support resources, financial aid options, and community connections for individuals navigating life with Chronic Myeloid Leukemia (CML). Find practical advice and empathetic guidance.
April 1, 2026
Explore targeted therapy for multiple myeloma. Learn how these precision treatments work, their types, potential side effects, and how they're used alongside other therapies to manage this blood cancer.
April 1, 2026